Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 100 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/50 microgram(s)/dose - salmeterol and fluticasone

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - salmeterol, fluticasone propionate - inhalation powder - salmeterol 50 µg fluticasone propionate 500 µg - drugs for obstructive airway diseases

United Kingdom - English - myHealthbox

3m health care ltd - salmeterol/fluticasone propionate - pressurised inhalation, suspension - 25microgram/125microgram - adrenergics and other anti-asthmatics - is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate

United Kingdom - English - myHealthbox

3m health care ltd - salmeterol/fluticasone propionate - pressurised inhalation, suspension - 25microgram/250microgram - adrenergics and other anti-asthmatics - it is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate

United Kingdom - English - myHealthbox

generics [uk] limited t/a mylan - salmeterol/fluticasone propionate - pressurised inhalation, suspension - 25microgram/125microgram - adrenergics and other anti-asthmatics - it is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate

United Kingdom - English - myHealthbox

generics (uk) ltd t/a mylan - salmeterol/fluticasone propionate - pressurised inhalation, suspension - 25microgram/250microgram - adrenergics and other anti-asthmatics - it is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate